[Federal Register Volume 81, Number 248 (Tuesday, December 27, 2016)]
[Notices]
[Pages 95145-95146]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-31143]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-N-4187]


Coordinated Registry Network for Devices Used for Acute Ischemic 
Stroke Intervention; Public Workshop; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
following public workshop entitled ``Coordinated Registry Network (CRN) 
for Devices Used for Acute Ischemic Stroke Intervention (DAISI).'' The 
purpose of the public workshop is to obtain stakeholders' input on the 
coordination of registries for DAISI.

DATES: The public workshop will be held on February 2, 2017, 8 a.m. to 
5 p.m. EST. The deadline for submitting comments regarding this public 
workshop is March 2, 2017. See the SUPPLEMENTARY INFORMATION section 
for registration date and information.

ADDRESSES: The public workshop will be held at the Ruth L. Kirschstein 
Auditorium, Natcher Conference Center, Bldg. 45, National Institutes of 
Health Campus, 9000 Rockville Pike, Bethesda, MD 20892. Entrance for 
the public workshop participants (non-NIH employees) is through the NIH 
Gateway Center located adjacent to the Medical Center Metro, where 
routine security check procedures will be performed. Please visit the 
following Web site for NIH campus location, parking, security, and 
travel information: http://www.nih.gov/about/visitor/index.htm. Please 
visit the following Web site for information on the Natcher Conference 
Center: http://www.genome.gov/11007522.
    You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    In order to permit the widest possible opportunity for public 
comment, FDA is soliciting either electronic or written comments on all 
aspects of the workshop topics.
    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Division of 
Dockets Management, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2016-N-4187 for ``Coordinated Registry Network (CRN) for Devices 
Used for Acute Ischemic Stroke Intervention (DAISI).'' Received 
comments will be placed in the docket and, except for those submitted 
as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Division of Dockets Management

[[Page 95146]]

between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' FDA will review 
this copy, including the claimed confidential information, in its 
consideration of comments. The second copy, which will have the claimed 
confidential information redacted/blacked out, will be available for 
public viewing and posted on https://www.regulations.gov. Submit both 
copies to the Division of Dockets Management. If you do not wish your 
name and contact information to be made publicly available, you can 
provide this information on the cover sheet and not in the body of your 
comments and you must identify this information as ``confidential.'' 
Any information marked as ``confidential'' will not be disclosed except 
in accordance with 21 CFR 10.20 and other applicable disclosure law. 
For more information about FDA's posting of comments to public dockets, 
see 80 FR 56469, September 18, 2015, or access the information at: 
http://www.fda.gov/regulatoryinformation/dockets/default.htm.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Division of Dockets Management, 5630 Fishers 
Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Jamie Waterhouse, Center for Devices 
and Radiological Health, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 66, Rm. 2611, Silver Spring, MD 20993, 301-796-
3063, email: [email protected].

SUPPLEMENTARY INFORMATION: 

I. Background

    Stroke is the fifth leading cause of death in the United States and 
the number one preventable cause of disability (Ref. 1). Recent 
publication of five prospective randomized trials and revised practice 
guidelines in the treatment of stroke has suggested the potential 
therapeutic role of endovascular therapy in combination with 
pharmacotherapy (typically intravenous tissue plasminogen activator (IV 
t-PA)) for patients with proximal large vessel occlusion stroke in the 
anterior circulation (M1 Middle Cerebral Artery segment with or without 
concomitant Internal Carotid Artery occlusion) (Refs. 2-6). FDA 
believes that research and development in this field, including the 
collection of data through the use of registries, provides a potential 
data source for expanding indications for already cleared/approved 
devices. Development and leveraging support for data collected within 
appropriate registries; with the participation of professional medical 
societies, industry, patient groups, healthcare facilities, and payers; 
can further drive innovation in this area and aid in the improvement of 
clinical care and patient outcomes. A coordinated registry network may 
also collect data reflective of clinical practice that is of sufficient 
quality and breadth to support scientific, clinical, and regulatory 
decision-making and aid in the design of future studies and performance 
testing requirements for new or existing devices.

II. Topics for Discussion at the Public Workshop

    This workshop is aimed at addressing scientific, clinical, and 
regulatory considerations associated with medical devices used in the 
treatment of acute ischemic stroke medical devices and the development 
of coordinated registry networks to serve the following topic areas:
     Clinical Common Data Elements;
     Standardized Definitions and Case Report Forms;
     Informatics, Sustainability, and Data Quality; and
     Additional scientific, methodological, and clinical 
considerations for evaluating information obtained from registries.

III. Participating in the Public Workshop

    To register for the public workshop, please visit FDA's Medical 
Devices News & Events--Workshops & Conferences (Medical Devices) 
calendar at http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm. Persons interested in attending this 
public workshop must register online by January 26, 2017, at 4 p.m. 
EST. Please provide complete contact information for each attendee, 
including name, title, affiliation, address, email, and telephone.
    Registration is free and based on space availability, with priority 
given to early registrants. Persons interested in attending this public 
workshop must register by January 26, 2017, at 4 p.m. EST. Early 
registration is recommended because seating is limited; therefore, FDA 
may limit the number of participants from each organization. 
Registrants will receive confirmation when they have been accepted. You 
will be notified if you are on a waiting list.
    If you need special accommodations due to a disability, please 
contact Peggy Roney, Center for Devices and Radiological Health, Office 
of Communication and Education, 301-796-5671, email: 
[email protected] no later than January 19, 2017.

IV. References

    The following references are on display in the Division of Dockets 
Management (see ADDRESSES) and are available for viewing by interested 
persons between 9 a.m. and 4 p.m., Monday through Friday; they are also 
available electronically at https://www.regulations.gov. FDA has 
verified the Web site addresses, as of the date this document publishes 
in the Federal Register, but Web sites are subject to change over time.

1. American Stroke Association, ``Impact of Stroke (Stroke 
statistics)'' (http://www.strokeassociation.org/STROKEORG/AboutStroke/Impact-of-Stroke-Stroke-statistics_UCM_310728_Article.jsp#.VvFGChvruUk).
2. Berkhemer, O. A., et al. ``A Randomized Trial of Intraarterial 
Treatment for Acute Ischemic Stroke.'' New England Journal of 
Medicine. 372, 11-20 (2015).
3. Saver, J. L., et al. ``Stent-Retriever Thrombectomy After 
Intravenous t-PA Versus t-PA Alone in Stroke.'' New England Journal 
of Medicine. 372, 2285-2295 (2015).
4. Goyal, M., et al. ``Randomized Assessment of Rapid Endovascular 
Treatment of Ischemic Stroke.'' New England Journal of Medicine. 
372, 1019-1030 (2015).
5. Campbell, B. C., et al. ``Endovascular Therapy for Ischemic 
Stroke with Perfusion-Imaging Selection.'' New England Journal of 
Medicine. 372, 1009-1018 (2015).
6. Jovin, T. G., et al. ``Thrombectomy Within 8 Hours After Symptom 
Onset in Ischemic Stroke.'' New England Journal of Medicine. 372, 
2296-2306 (2015).

    Dated: December 20, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-31143 Filed 12-23-16; 8:45 am]
BILLING CODE 4164-01-P